Global Oncology Cancer Drugs Market in North America,Europe 2013-2020
Big Market Research, Global Oncology/Cancer Drugs Market Size, Share, Global Trends, Company Profiles, Product type, Applications, Component, End User, Geography, Demand, Insights, Segmentation and Forecast, 2013 – 2020.Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market. Get full report @ http://www.bigmarketresearch.com/oncology-cancer-drugs-market
Big Market Research, Global Oncology/Cancer Drugs Market Size, Share, Global Trends, Company Profiles, Product type, Applications, Component, End User, Geography, Demand, Insights, Segmentation and Forecast, 2013 – 2020.Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market.
Get full report @ http://www.bigmarketresearch.com/oncology-cancer-drugs-market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Global</strong><br />
<strong>Oncology</strong>/<strong>Cancer</strong> <strong>Drugs</strong><br />
<strong>Market</strong> (Therapeutic<br />
Modalities, <strong>Cancer</strong><br />
Types and Geography)<br />
www.bigmarketresearch.com
Report Description<br />
Acquired (Autoimmune) Hemolytic Anemia<br />
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred<br />
option for treat<strong>in</strong>g various cancer types, especially for blood cancer (leukemia). Ris<strong>in</strong>g<br />
<strong>in</strong>cidence of various cancer conditions, grow<strong>in</strong>g popularity of advance therapies<br />
(biological and targeted drug therapies), patents expiration of lead<strong>in</strong>g drugs along with<br />
commercialization of biosimilars are the few factors driv<strong>in</strong>g the growth of global oncology<br />
drugs market. However, high cost <strong>in</strong>volved <strong>in</strong> new drug development coupled with threat<br />
of failure and adverse effects associated with cancer drugs therapies would restra<strong>in</strong> the<br />
growth of the market. Commercialization of advanced therapeutics such as targeted and<br />
immunotherapies would reduce the negative <strong>in</strong>fluence of restra<strong>in</strong>ts and fuel the market<br />
growth.<br />
Read complete report here @<br />
http://www.bigmarketresearch.com/oncology-cancer-drugs-market
Report Description<br />
Acquired (Autoimmune) Hemolytic Anemia<br />
The global oncology drugs market is expected to reach at $111.9 billion by <strong>2020</strong>. Patent<br />
expiration of key cancer drugs such as Hercept<strong>in</strong>, Erbitux, Rituxan and Avast<strong>in</strong>, is<br />
expected to boost the growth of cancer biosimilars market by <strong>2020</strong>. Go<strong>in</strong>g further, the<br />
biological therapies are expected to dom<strong>in</strong>ate the market by <strong>2020</strong>, due to their high<br />
efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest<br />
revenue generat<strong>in</strong>g segment <strong>in</strong> <strong>2013</strong> ow<strong>in</strong>g to the high cost of drugs (immunotherapies)<br />
used for the treatment of blood cancer.<br />
Download Sample Report @<br />
http://www.bigmarketresearch.com/request-sample/22695
Report Description<br />
Acquired (Autoimmune) Hemolytic Anemia<br />
Geographically, <strong>North</strong> <strong>America</strong>, dom<strong>in</strong>ates the market followed by <strong>Europe</strong>. <strong>North</strong> <strong>America</strong><br />
accounted for about ~38% share <strong>in</strong> the overall oncology drugs market <strong>in</strong> <strong>2013</strong> ow<strong>in</strong>g to<br />
the heavy <strong>in</strong>vestments by mult<strong>in</strong>ational companies <strong>in</strong> research and development of<br />
cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and<br />
high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would<br />
grow at the promis<strong>in</strong>g CAGR of 8.7% dur<strong>in</strong>g the forecast period. Such high growth rate is<br />
majorly due to <strong>in</strong>creas<strong>in</strong>g awareness towards advanced therapies namely<br />
immunotherapies and <strong>in</strong>crease <strong>in</strong> per capita healthcare spend<strong>in</strong>g.<br />
Key companies profiled <strong>in</strong> the report are Roche diagnostics, Novartis AG, Celgene<br />
Corporation, AstraZeneca, Johnson & Johnson, Merck & Co., Eli Lilly & Co. and<br />
GlaxoSmithKl<strong>in</strong>e. Companies operat<strong>in</strong>g <strong>in</strong> the cancer drugs market focus on several<br />
strategies such as collaboration, approval and acquisition.<br />
Get enquire about report here @<br />
http://www.bigmarketresearch.com/report-enquiry/22695
Table Of Contents<br />
Acquired (Autoimmune) Hemolytic Anemia<br />
CHAPTER 1 INTRODUCTION<br />
CHAPTER 2 EXECUTIVE SUMMARY<br />
CHAPTER 3 MARKET OVERVIEW<br />
CHAPTER 4 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES<br />
CHAPTER 5 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES<br />
CHAPTER 6 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY<br />
CHAPTER 7 COMPANY PROFILES<br />
Read complete TOC @<br />
http://www.bigmarketresearch.com/oncology-cancer-drugs-market
Report Description<br />
Acquired (Autoimmune) Hemolytic Anemia<br />
KEY BENEFITS<br />
The report provides the quantitative analysis of the current market and estimations<br />
through <strong>2013</strong>-<strong>2020</strong> that assists <strong>in</strong> identify<strong>in</strong>g the prevail<strong>in</strong>g market opportunities to<br />
capitalize on<br />
The report helps <strong>in</strong> understand<strong>in</strong>g the strategies adopted by various companies for<br />
ga<strong>in</strong><strong>in</strong>g market share <strong>in</strong> the cancer drugs market<br />
The report provides comprehensive analysis of factors that drive and restrict the growth<br />
of the cancer drugs market<br />
<strong>Market</strong> conditions of cancer drugs market across all geographic regions are<br />
comprehensively analyzed<br />
Competitive <strong>in</strong>telligence (of lead<strong>in</strong>g manufacturers) helps <strong>in</strong> understand<strong>in</strong>g the<br />
competitive scenario across the geographies<br />
SWOT analysis of the key market players is provided to illustrate the bus<strong>in</strong>ess strategies<br />
adopted by the companies
Report Description<br />
Acquired (Autoimmune) Hemolytic Anemia<br />
MARKET SEGMENTATION<br />
The cancer drugs market is segmented by the therapeutic modalities, cancer types and<br />
geography.<br />
MARKET BY THERAPEUTIC MODALITIES<br />
• Chemotherapy<br />
• Targeted Therapy<br />
• Immunotherapy (Biologic Therapy)<br />
• Hormonal Therapy<br />
• Others<br />
MARKET BY CANCER TYPES<br />
• Blood <strong>Cancer</strong><br />
• Breast <strong>Cancer</strong><br />
• Gastro<strong>in</strong>test<strong>in</strong>al <strong>Cancer</strong><br />
• Prostate <strong>Cancer</strong>
Report Description<br />
Acquired (Autoimmune) Hemolytic Anemia<br />
MARKET BY GEOGRAPHY<br />
• <strong>North</strong> <strong>America</strong><br />
• United States<br />
• Canada<br />
• Mexico<br />
• <strong>Europe</strong><br />
• Germany<br />
• France<br />
• United K<strong>in</strong>gdom<br />
• Others<br />
• Asia-Pacific<br />
• India<br />
• Ch<strong>in</strong>a<br />
• Japan<br />
• Australia<br />
• Others<br />
• LAMEA<br />
• GCC (Gulf Corporation Council)
Report Description<br />
Acquired (Autoimmune) Hemolytic Anemia<br />
MARKET BY GEOGRAPHY<br />
• <strong>North</strong> <strong>America</strong><br />
• <strong>Europe</strong><br />
• Asia-Pacific<br />
• LAMEA<br />
Request for Discount @<br />
http://www.bigmarketresearch.com/purchase-enquiry/22695
FOR MORE DETAILS<br />
Visit us at :<br />
http://www.bigmarketresearch.com/oncology-cancer-drugsmarket<br />
Stay With Us:<br />
TELEPHONE: +1 (855) 711-1555<br />
E-MAIL: help@bigmarketresearch.com<br />
5933 NE W<strong>in</strong> Sivers Drive,<br />
#205, Portland, OR 97220<br />
United States
Change language